Prof. Reinhard Dummer joins Oncobit as Senior Medical Advisor
We are excited to welcome Prof. Reinhard Dummer to Oncobit as Senior Medical Advisor. Prof. Dummer is a highly cited Professor of Dermatology at the University Zurich. He is renowned for his extensive contributions to skin cancer research, particularly in melanoma and non-melanoma skin cancers at the University Hospital Zurich. As Senior Medical Advisor, Prof. Dummer will play a key role in guiding Oncobit’s clinical strategies, and fostering collaborations with leading medical institutions and industry partners.
We are thrilled to announce that we closed a 1.5M CHF Pre-Series A Financing round. A huge thank you to our existing and new investors for supporting our vision of enabling personalized cancer care. The investment will enable us to continue to grow and strengthen our position in the cancer monitoring market.
Oncobit announces changes to the Board of Directors
Oncobit, a pioneer in precision cancer monitoring solutions, is pleased to announce changes to its Board of Directors. With the achievement of CE marking for our products and first revenues in Europe, the company focus shifts from product validation to clinical and commercial expansion. Following this shift the changes to the board composition,
pave the way for the company’s future success. The whole Oncobit team extends heartfelt gratitude to Dr. Tomas Hruz for his invaluable contributions in the areas of bioinformatic analyses and intellectual property and warmly welcomes Prof. Mitch Levesque and Bram Goorden, MBA as new members.
Oncobit Receives European Regulatory Approval (IVDR Certification) for Melanoma ctDNA Monitoring Tests
We are pleased to announce that we received the In Vitro Diagnostic Regulation (IVDR) certification for our Oncobit PM melanoma test suite, which allows us to CE-mark these tests and to offer them for clinical use. Oncobit PM is designed to detect specific cancer markers in the tumor-derived fraction of circulating cell-free DNA (ctDNA) isolated from the blood of melanoma patients. Oncobit PM tests detect specific cancer hot spot mutations in the genes BRAF, NRAS, GNAQ, GNA11, and SF3B1, critical for cutaneous and uveal melanoma.
Oncobit PM Established at 3 Leading Cancer Centers in Germany
We are proud to share that our Oncobit™ PM ctDNA analysis tests are now in use at three prominent cancer centers across Germany, including the University Medical Center Hamburg-Eppendorf (UKE) led by Prof. Christoffer Gebhardt and the Hauttumorcentrum Charité (HTCC) Charité under the guidance of Prof. Thomas Eigentler.
Our advanced Oncobit PM tests play a pivotal role in addressing various issues related to cancer monitoring. Specifically, these esteemed institutions will utilize our tests to generate crucial clinical utility data. This data will not only contribute to the advancement of medical knowledge, but will also enhance patient care by providing valuable insights into cancer management.
By establishing our test at these leading study sites, we are pushing the boundaries of cancer research and treatment strategies. Together with UKE Hamburg and the Hauttumorcentrum Charité (HTCC), we're committed to making a positive impact on patient outcomes and contributing to the future of personalized medicine.
Oncobit announces partnership with Immunocore to advance therapy response analysis in clinical trials
We are thrilled to announce that we have signed a service agreement with Immunocore Holdings plc (NASDAQ: IMCR), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases. This collaboration aims to improve the use and understanding of circulating tumor DNA (ctDNA) analysis as a reliable and real time therapy response marker in clinical trials.
Exciting collaboration with the National Cancer Institute and Klaipeda University Hospital in Lithuania for the BIOMELKID study.
We are delighted to announce that Oncobit is collaborating with the National Cancer Institute (NCI) on the BIOMELKID trial. Our joint mission: To identify predictive and prognostic biomarkers in metastatic melanoma patients undergoing immunotherapy.
Professor Vincas Urbonas and his team at the NCI are leading this impactful project focused on the study of ctDNA in melanoma patients. With our Oncobit PM digital PCR solutions, we are pleased to provide a powerful tool to reliably quantify ctDNA. Our shared goal is to unlock the secrets of circulating tumor DNA to better understand disease progression and treatment response.
Aiming to improve patient care!
Oncobit among the top 3 finalists for the Swiss Excellence Product Awards 2023
Each year, the Swiss Excellence Foundation honors a Swiss start-up with the Swiss Excellence Award 2023 for an innovative product. The products are judged on their innovative content, their value creation potential and the quality of their business model and marketing concept. Oncobit is pleased to have made it to the finalists and congratulates Perovskia Solar AG for winning the award for its revolutionary and adaptable solar cells.
We exhibited at the 33rd Skin Cancer Congress and the ADO Annual Meeting in Hamburg
It was fantastic to experience the shared enthusiasm and determination to push the boundaries of melanoma care at the ADO meeting. In addition to receiving medical update on clinical trials, we have made significant progress with our projects on the monitoring of uveal melanoma with our Oncobit PM assays. We look forward to sharing more details of these developments in the near future.
Manage Consent
This website uses cookies to provide the best possible functionality. We distinguish between functional cookies, which are necessary for the smooth functioning of the website, and optional cookies, which are used for marketing purposes.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.